Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0HZ2E
|
|||
| Former ID |
DNC000911
|
|||
| Drug Name |
M100907
|
|||
| Synonyms |
Volinanserin; 139290-65-6; UNII-EW71EE171J; (R)-(2,3-Dimethoxyphenyl)(1-(4-fluorophenethyl)piperidin-4-yl)methanol; CHEMBL74355; EW71EE171J; (R)-(+)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUORO-PHENYL)ETHYL]-4-PIPERIDINE METHANOL; M-100907; (R)-(2,3-dimethoxyphenyl)-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]methanol; Volinanserin [INN]; Serotonin 5-HT2 Receptor Antagonists; VOLINANSERIN
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Sleep-wake disorder [ICD-11: 7A00-7B2Z; ICD-10: G47] | Phase 3 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H28FNO3
|
|||
| Canonical SMILES |
COC1=CC=CC(=C1OC)C(C2CCN(CC2)CCC3=CC=C(C=C3)F)O
|
|||
| InChI |
1S/C22H28FNO3/c1-26-20-5-3-4-19(22(20)27-2)21(25)17-11-14-24(15-12-17)13-10-16-6-8-18(23)9-7-16/h3-9,17,21,25H,10-15H2,1-2H3/t21-/m1/s1
|
|||
| InChIKey |
HXTGXYRHXAGCFP-OAQYLSRUSA-N
|
|||
| CAS Number |
CAS 139290-65-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7979872, 11056395, 12014670, 14755501, 14804188, 39340971, 80773858, 91616570, 103275460, 103992797, 114155712, 124954269, 128128333, 134341108, 135650573, 137231458, 143057684, 144210564, 162249020, 164766144, 170500892, 176224358, 185997000, 198966064, 208265419, 215780295, 223532818, 223782286, 226970760, 241034286, 249735007, 252157845, 252159862, 252322025, 252821118
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 2A receptor (HTR2A) | Target Info | Antagonist | [2], [3] |
| 5-HT 2C receptor (HTR2C) | Target Info | Inhibitor | [4] | |
| Voltage-gated potassium channel Kv11.1 (KCNH2) | Target Info | Inhibitor | [4] | |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Gap junction | ||||
| Serotonergic synapse | ||||
| Inflammatory mediator regulation of TRP channels | ||||
| Panther Pathway | 5HT2 type receptor mediated signaling pathway | |||
| Pathwhiz Pathway | Muscle/Heart Contraction | |||
| Reactome | Serotonin receptors | |||
| G alpha (q) signalling events | ||||
| Voltage gated Potassium channels | ||||
| WikiPathways | Serotonin Receptor 2 and STAT3 Signaling | |||
| Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | ||||
| SIDS Susceptibility Pathways | ||||
| Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| Hematopoietic Stem Cell Differentiation | ||||
| Potassium Channels | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00495885) Efficacy and Safety of M100907 on Sleep Maintenance Insomnia With a Sub-study in Stable Type II Diabetes Mellitus. U.S. National Institutes of Health. | |||
| REF 2 | Antagonism of 5-hydroxytryptamine(2a) receptors attenuates the behavioral effects of cocaine in rats. J Pharmacol Exp Ther. 2001 Apr;297(1):357-63. | |||
| REF 3 | Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET. Bioorg Med Chem. 2009 Apr 15;17(8):2989-3002. | |||
| REF 4 | Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists ... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3708-12. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.